Our Team

A multidisciplinary group of medical and scientific experts committed to empowering the MEK2 Research Foundation and the CFC community.

MEK2 Research Foundation President

Founder and President of the MEK2 Research Foundation, Co-founder of RASopathies Poland, and member of the Scientific Committee for CFC International, the EURAS Patient Council, and the Patient Advisory Board within the European network ERN ITHACA.

A dedicated leader and advocate in the rare disease community, she has long been involved in science communication and educational content creation. She uses her experience to advance research on MEK2 mutations and other RASopathies, while building meaningful connections between scientists, clinicians, and families worldwide. Her work also focuses on health policy advocacy and raising public awareness of ultra-rare diseases.

Her greatest motivation is Maria – her daughter, diagnosed with CFC type 4 caused by a MEK2 mutation. In her free time, she enjoys reading, writing, and creating stories across genres, from contemporary fiction and reportage to children’s literature.

Medical University of Warsaw

Works at the Department of Medical Genetics of the Medical University of Warsaw and at the Neurodiagnostics and Neurogenetics Unit of the Children’s Clinical Hospital WUM. He is the Head of the Center for Rare and Undiagnosed Diseases at WUM and serves as a genetic consultant in pediatric and adult hospital units.

VIZJA University in Warsaw

A neurobiologist conducting research on mouse models of neurological diseases. He obtained his PhD at the Nencki Institute of Experimental Biology and completed a postdoctoral fellowship at the University of California, Santa Cruz. His work focuses on autism spectrum disorders, addiction mechanisms, and ultra-rare diseases, integrating neurobiology, genetics, and pharmacology.

Harvard University

Żaneta Matuszek jest badaczką podoktorską na Uniwersytecie Harvarda w laboratorium Paoli Arlotty, gdzie bada mechanizmy choroby Huntingtona z wykorzystaniem modeli ludzkiego mózgu in vitro. Wcześniej pracowała w Broad Institute w zespole Davida Liu, rozwijając podejścia terapeutyczne oparte na technologii CRISPR dla chorób neurologicznych. Wykształcenie zdobyła na Uniwersytecie Warszawskim oraz Uniwersytecie Harvarda.

Institute of Mother and Child

Professor at the Institute of Mother and Child, laboratory diagnostician, and specialist in medical laboratory genetics, certified by the European Board of Medical Geneticists (EBMG). She leads the Developmental Genetics Laboratory and coordinates the national newborn screening program for spinal muscular atrophy (SMA).

Maj Institute of Pharmacology, Polish Academy of Sciences

Researcher at the Maj Institute of Pharmacology, Polish Academy of Sciences, specializing in computer-aided drug design. Her interests include virtual screening, molecular docking, and molecular dynamics simulations. Within the MEK2 Research Foundation, she supports studies on MEK2 molecular mechanisms and therapeutic strategies for CFC4 patients.

Medical University of Warsaw

Pediatrician and pediatric cardiologist, Assistant Professor at the Medical University of Warsaw and senior physician at the Children’s Clinical Hospital UCK WUM. He is the principal investigator of the MEKinRAS project evaluating trametinib in hypertrophic cardiomyopathy in children with RASopathies. Recipient of the Polish Ministry of Education and Science Scholarship for Young Scientists.

Independent Researcher

He obtained a PhD in molecular neurobiology at the Free University of Amsterdam and completed postdoctoral training focused on nuclear hormone and G-protein coupled receptor signaling at Erasmus MC and the Free University of Amsterdam. He later led multidisciplinary teams in biotechnology, overseeing early-stage drug discovery, technology development, and lab automation. He has extensive experience leading high-throughput screening programs and coordinating drug repurposing projects for ultra-rare diseases.

Maj Institute of Pharmacology, Polish Academy of Sciences

Molecular biologist affiliated with the Pharmacogenomics Laboratory at the Maj Institute of Pharmacology. Her research focuses on molecular neurobiology and the genetics of neurodevelopmental disorders. She studies drug and receptor mechanisms at the genomic and transcriptomic levels.

Łukasiewicz – PORT Polish Center for Technology Development

Dr. Ślęzak is a neuroscientist and Group Leader of the “Biology of Astrocytes” Research Group at Łukasiewicz – PORT in Wrocław, focusing on the molecular mechanisms of psychiatric disorders using advanced genetic and translational approaches. He received his PhD in Life Sciences from the University of Louis Pasteur in Strasbourg and currently serves as Vice-President of the Polish Neuroscience Society (2023–2027).

Medical University of Gdańsk

Assistant Professor at the Department of Pediatrics, Hematology, and Oncology, Medical University of Gdańsk. She is affiliated with the Rare Diseases Center at UCK, where she provides care for children with genetic and oncological conditions. Within the MEK2 Research Foundation, she supports international clinical collaboration.

Ulm University

An immunologist specialising in lymphocyte development and post-transcriptional regulation of gene expression. He obtained his PhD at the Helmholtz Centre for Infection Biology and completed his habilitation at the Ludwig Maximilian University of Munich. He leads a research group at Ulm University Medical Centre, studying immune mechanisms in children, and his team is affiliated with the German Center for Child and Adolescent Health (DZKJ).

Fraunhofer ITMP-TNM & University Medical Center Göttingen

Biomedical researcher and independent group leader in Göttingen, Germany leading two research groups: the Stem Cell Unit at the University Medical Center and his group at the Fraunhofer ITMP. His research focuses on human iPSC-based disease modeling across genetically driven cardiac and neurodevelopmental disorders, with a particular emphasis on RASopathies. His overarching goal is the development and translation of personalized therapies, including genotype-tailored compounds and CRISPR-based gene therapies.

Medical University of Warsaw

Pediatric neurologist working at the Children’s Clinical Hospital of Józef Polikarp Brudziński in Warsaw. He specializes in the diagnosis and treatment of neurological disorders in children. His clinical practice includes a strong focus on rare diseases.

Maj Institute of Pharmacology, Polish Academy of Sciences

PhD student at the Department of Medicinal Chemistry, Maj Institute of Pharmacology. Within the MEK2 Research Foundation, she performs molecular modeling of the MEK2 protein and in silico simulations using MEK inhibitors. She is a co-author of a molecular review on MEK2 structure, function, and therapeutic targets.

Medical University of Warsaw

Fifth-year medical student at the Medical University of Warsaw. Within the MEK2 Research Foundation, she analyzes clinical features and the natural history of CFC type 4 syndrome. She is a co-author of a case report and a clinical review focused on CFC4.

Medical University of Warsaw

Fourth-year medical student at the Medical University of Warsaw. At the MEK2 Research Foundation, he develops strategies for oligonucleotide-based therapies and analyzes the potential of prime and base editing in rare diseases. His interests include molecular mechanisms of gene therapies and drug interactions.

Nencki Institute of Experimental Biology of the Polish Academy of Sciences

PhD student at the Nencki Institute of Experimental Biology. She collaborates with MEK2 Research on cellular and translational studies. Her work focuses on signaling pathways involving the MEK2 protein.